EirGenix (6589) - Total Liabilities
Based on the latest financial reports, EirGenix (6589) has total liabilities worth NT$1.94 Billion TWD (≈ $61.13 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EirGenix - Total Liabilities Trend (2017–2024)
This chart illustrates how EirGenix's total liabilities have evolved over time, based on quarterly financial data. Check EirGenix (6589) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
EirGenix Competitors by Total Liabilities
The table below lists competitors of EirGenix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hovnanian Enterprises Inc
NYSE:HOV
|
USA | $2.00 Billion |
|
Suzhou Kingswood Printing Ink Co Ltd
SHE:300192
|
China | CN¥255.93 Million |
|
Anshan Senyuan Road Bridge
SHE:300210
|
China | CN¥587.19 Million |
|
Dexterra Group Inc
TO:DXT
|
Canada | CA$467.63 Million |
|
IntelliEPI Cayman
TWO:4971
|
Taiwan | NT$127.53 Million |
|
MiMedx Group Inc
NASDAQ:MDXG
|
USA | $80.04 Million |
|
Just Dial Limited
NSE:JUSTDIAL
|
India | Rs9.38 Billion |
|
China Fortune Land Development Co Ltd
SHG:600340
|
China | CN¥259.93 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down EirGenix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EirGenix assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EirGenix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EirGenix (2017–2024)
The table below shows the annual total liabilities of EirGenix from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.62 Billion ≈ $50.98 Million |
+41.31% |
| 2023-12-31 | NT$1.15 Billion ≈ $36.08 Million |
-1.65% |
| 2022-12-31 | NT$1.16 Billion ≈ $36.68 Million |
+15.03% |
| 2021-12-31 | NT$1.01 Billion ≈ $31.89 Million |
-47.55% |
| 2020-12-31 | NT$1.93 Billion ≈ $60.79 Million |
+1558.06% |
| 2019-12-31 | NT$116.38 Million ≈ $3.67 Million |
-86.89% |
| 2018-12-31 | NT$887.57 Million ≈ $27.96 Million |
+61.21% |
| 2017-12-31 | NT$550.56 Million ≈ $17.35 Million |
-- |
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more